{"id":"W4412526890","doi":"10.1038/s41591-025-03895-1","title":"Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial","year":2025,"lang":"en","type":"erratum","venue":"Nature Medicine","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Oncolytic virus; Pembrolizumab; Virotherapy; Glioblastoma; Medicine; Oncology; Internal medicine; Immunotherapy; Cancer research; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003767419,0.001196615,0.001410684,0.001146124,0.001195331,0.002137809,0.002164462,0.003958948,0.03251375],"category_scores_gemma":[0.02317005,0.0005961316,0.001302683,0.001095517,0.0008297853,0.0009190697,0.0006298093,0.00796502,0.01282544],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002659474,"about_ca_system_score_gemma":0.003465605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007531096,"about_ca_topic_score_gemma":0.01409615,"domain_scores_codex":[0.9980925,0.0003319093,0.0002855991,0.0003179969,0.0008307027,0.0001413058],"domain_scores_gemma":[0.9913085,0.002677291,0.0004501214,0.0004231535,0.004471527,0.0006693635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001091519,0.000007550538,0.0000415221,0.0001127852,0.00002176909,0.0002030025,0.000008531649,0.00004031286,0.00007864841,0.0002889892,0.993451,0.005636675],"study_design_scores_gemma":[0.000568076,0.00009461043,0.0009363226,0.0005720769,0.0002397117,0.001318558,0.00004301194,0.0004537374,0.001350588,0.001367539,0.9930022,0.00005353943],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"other","genre_scores_codex":[0.0004264353,0.002003781,0.001129244,0.0685445,0.9214706,0.00006052119,0.002201852,0.0003716291,0.003791427],"genre_scores_gemma":[0.03146403,0.01654596,0.01016903,0.225595,0.3832228,0.0005118781,0.006643162,0.0025392,0.323309],"genre_candidate":"other","genre_consensus":null,"teacher_disagreement_score":0.03251375,"threshold_uncertainty_score":0.1087693,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01628008110443549,"score_gpt":0.3825422591962199,"score_spread":0.3662621780917844,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}